Publication:
Role of natural killer cells in lung cancer

dc.contributor.coauthorAktaş, Özge Nur
dc.contributor.kuauthorErman, Baran
dc.contributor.kuauthorErus, Suat
dc.contributor.kuauthorTanju, Serhan
dc.contributor.kuauthorDilege, Şükrü
dc.contributor.kuauthorÖztürk, Ayşe Bilge
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileFaculty Member
dc.contributor.researchcenterKoç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM)
dc.contributor.unitKoç University Hospital
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.contributor.yokid147629
dc.date.accessioned2024-11-09T13:07:04Z
dc.date.issued2018
dc.description.abstractPurpose: One of the key immune cells involved in the pathogenesis of lung cancer is natural killer (NK) cells and these cells are novel targets for therapeutic applications in lung cancer. The purpose of this review is to summarize the current literature on lung cancer pathogenesis with a focus on the interaction between NK cells and smoking, how these factors are related to the pathogenesis of lung cancer and how NK cell-based immunotherapy effect lung cancer survival. Methods: The relevant literature from PubMed and Medline databases is reviewed in this article. Results: The cytolytic potential of NK cells are reduced in lung cancer and increasing evidence suggests that improving NK cell functioning may induce tumor regression. Recent clinical trials on NK cell-based novel therapies such as cytokines including interleukin (IL)-15, IL-12 and IL-2, NK-92 cell lines and allogenic NK cell immunotherapy showed promising results with less adverse effects on the lung cancer survival. Conclusions: The NK cell targeting strategy has not yet been approved for lung cancer treatment. More clinical studies focusing on the role of NK cells in lung cancer pathogenesis are warranted to develop novel NK cell-based therapeutic approaches for the treatment of lung cancer.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionAuthor's final manuscript
dc.description.volume144
dc.formatpdf
dc.identifier.doi10.1007/s00432-018-2635-3
dc.identifier.eissn1432-1335
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR01562
dc.identifier.issn0171-5216
dc.identifier.linkhttps://doi.org/10.1007/s00432-018-2635-3
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85044721517
dc.identifier.urihttps://hdl.handle.net/20.500.14288/2547
dc.identifier.wos431930800001
dc.keywordsImmunotherapy
dc.keywordsLung cancer
dc.keywordsNatural killer cells
dc.keywordsNon-small cell lung cancer
dc.keywordsSmall cell lung cancer
dc.languageEnglish
dc.publisherSpringer
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8184
dc.sourceJournal of Cancer Research and Clinical Oncology
dc.subjectOncology
dc.titleRole of natural killer cells in lung cancer
dc.typeReview
dspace.entity.typePublication
local.contributor.authoridN/A
local.contributor.authoridN/A
local.contributor.authoridN/A
local.contributor.authoridN/A
local.contributor.authorid0000-0003-0166-424X
local.contributor.kuauthorErman, Baran
local.contributor.kuauthorErus, Suat
local.contributor.kuauthorTanju, Serhan
local.contributor.kuauthorDilege, Şükrü
local.contributor.kuauthorÖztürk, Ayşe Bilge

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
8184.pdf
Size:
666.38 KB
Format:
Adobe Portable Document Format